As COVID-19 is raging across the United States, researchers are studying how the virus can cause serious damage to the human body, especially for those who already have chronic diseases.
After preliminary observations of 200 COVID-19 patients with severe hyperglycemia, researchers from the University of Michigan have clarified in a new paper why hyperglycemia may lead to a worse prognosis for people infected with the virus. Researchers have developed a blood sugar management tool that can reduce the risk of secondary infections, kidney disease and intensive care in patients with diabetes, prediabetes or obesity with COVID-19.
"According to our preliminary observations of patients, patients with one of the above diseases are very likely to cause more severe respiratory dysfunction after contracting the new crown, and may even lead to death," said first author Dr. Roma Gianchandani.
Senior author, Professor of Diabetes, Dr. Rodica Pop-Busui suspects that the low inflammation of diabetes and hyperglycemia will promote a surge in viral inflammation, leading to insulin resistance and severe hyperglycemia. She said: “When the human body becomes inflamed, it triggers an abnormal immune response, which not only attacks the virus, but also affects the rest of the body’s healthy cells and tissues, resulting in a rapid deterioration in health.” Specifically, these patients suffer from kidney failure. Mechanical ventilation is required, the risk of renal replacement therapy increases, and drugs called vasopressors are needed to stop dangerous low blood pressure or use steroids to combat acute respiratory distress syndrome. Gianchandani said: "All these complications make blood glucose management more difficult, but we firmly believe that this management is essential to prevent complications that lead to prolonged hospital stays or onset. A recent study has shown that good blood glucose control is associated with signs of inflammation. There is a correlation between the decrease in the level of the substance." The research team has developed a tool to identify and manage hyperglycemia in COVID-19 patients and place it in certain risk categories, including hyperglycemia severity, obesity, insulin resistance level, and degree of renal dysfunction , Inflammation markers, etc.